Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival by Ragnarsson, G et al.
The majority of invasive human solid tumours are considered to be
sporadic. Accumulation of multiple genetic alterations play a
major part in tumorigenesis of these tumours. Mutations cause
some genes (proto-oncogenes) to gain function while other genes
[tumour-suppressor genes (TSG)] sustain loss of function (for
review see Haber and Harlow, 1997). The localization of these
genes to specific chromosome regions is currently a major area of
study in cancer research. Loss or inactivation of TSG has been
shown to be a major feature in the genesis of the solid cancers
examined so far (Cavenee and White, 1995). As a full inactivation
of a gene usually requires the silencing of both its alleles, the first
inactivating mutation is, by inference, recessive. This first muta-
tion can be somatic or passed through the germ line. The second
mutation is somatic and proceeds through a chromosomal mecha-
nism, which leads to loss of the wild-type allele (loss of heterozy-
gosity) or replacement of the wild type allele by the mutant allele.
The result is a complete absence of the normal protein product.
Loss of heterozygosity (LOH) on the short arm of chromosome 1
in solid human tumours has been reported in the following cancer
types: breast cancer, neuroblastoma, mesothelioma, melanoma, testis
cancer, liver cancer, stomach cancer, phaeochromocytoma, thyroid
cancer, meningioma, colorectal cancer, endometrial cancer and
Wilms tumour (Mathew et al, 1987; Dracopoli et al, 1989; Chen et al,
1992; Bardi et al, 1993; Taguchi et al, 1993; Bello et al, 1994; Bieche
et al, 1994; Mathew et al, 1994; Stock et al, 1994; Yeh et al, 1994;
Caron et al, 1995; Kuroki et al, 1995; Munn et al 1995; White et al,
1995; Di Vinci et al, 1996; Ezaki et al, 1996; Ragnarsson et al, 1996;
Ogunbiyi et al, 1997; Vargas et al, 1997;  Arlt et al, 1996; Steenman
et al, 1997). All of these studies strongly indicate that TSGs may be
located on the short arm of chromosome 1. A number of studies have
shown a significant association between LOH at 1p and prognostic
factors. The distal half of chromosome 1p from 1p31.1 to 1p36.3 is
among the regions on 1p that have shown frequent LOH. At least two
studies have shown an association between LOH at 1p and amplifi-
cation of the N-myc proto-oncogene in breast tumours and neuro-
blastoma (Bieche et al, 1994; Caron et al, 1995). There seems to be
an association between LOH at 1p and poor prognosis in patients
with neuroblastoma (Caron et al, 1996), breast cancer (Ragnarsson et
al, 1996) and colon cancer (Ogunbiyi et al, 1997). LOH at 1p was
shown to be an early event in the carcinogenesis of breast cancer
(Munn et al, 1995), liver cancer (Kuroki et al, 1995) and colorectal
cancer (Di Vinci et al, 1996). One study indicates that LOH at 1p is a
late event in melanomas (Dracopoli et al, 1989). Introduction of
chromosome 1p36 into colon cancer cell line suppresses tumorigenic
behaviour (Tanaka et al, 1993).
In this study we made an attempt to discover whether LOH
patterns were similar in different types of human solid cancers. We
screened 682 human solid tumours from 20 different locations
for loss of heterozygosity at chromosome 1p, using 15 highly
polymorphic microsatellite markers focusing on 1p31-pter.
Furthermore, we tested whether there was an association between
LOH at 1p and overall patient survival and clinico-pathological
variables.
MATERIALS AND METHODS
Patients and tumour material
Fresh tumour samples from 683 primary solid tumours and normal
tissue samples from the same patients were obtained on the day of
surgery, immediately frozen and stored at – 70°C. The tumours
were from the following locations (number of tumours investi-
gated in parentheses): breast (238); colon and rectum (109);
kidney (73); lung (63); stomach (38); ovary (31); testis (30);
endometrium (25); thyroid (14); sarcoma (14); lymphoma (8);
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oesophagus (6); liver (6); mouth (5); brain (5); pancreas (4);
prostate (3); skin (3); adrenal gland (2); and unknown origin (6). In
the case of the breast cancer patients, peripheral blood leukocytes
were the source of normal DNA. Breast tumours were collected
from the year 1987 to 1994 but other solid tumours from 1991 to
1997. All information about the tumours, e.g. size, type, age at
diagnosis, histology and node status, was recorded at the
Department of Pathology, University Hospital of Iceland.
DNA extraction and analysis
Tumour and normal DNA was extracted from the tissue samples
with proteinase K using a method developed for paraffin-embedded
tissue (Smith et al, 1992). In the case of the breast samples, normal
DNA was extracted from peripheral blood leukocytes by a salting-
out method (Miller et al, 1988) and tumour DNA was extracted
according to standard protocols. Paired blood and tumour DNA
was subjected to PCR analysis. DynaZymeTM polymerase (from
Finnzymes Oy, Espoo, Finland) was used in the buffer solution
provided by the manufacturer. Samples were subjected to 35 cycles
of amplification, consisting of 30 s at 94°C, 40 s at 55°C and 30 s at
72°C, followed by 10 min at 72°C. The markers used (Table 1)
were obtained from Research Genetics (Huntsville, AL, USA).
Primers were elongated by terminal-transferase in 40 mM K-
HEPES/1 mM CoCl2 buffer at pH 7.2 and 37°C over night. PCR
products were separated on 6.5% polyacrylamide 8 M urea
sequencing gels and transferred to a Hybond-N+ nylon film
(Amersham, Aylesbury, UK). They were then hybridized for at
least 2 h at 42°C with the elongated primers, covalently labelled
with peroxidase (ECL kit, Amersham, Aylesbury, UK). The
membranes were washed once in 3 ´ SSC/0.1% SDS at 39–42°C
and then twice in 0.2 ´ SSC at 39–42°C. After washing, the
membranes were bathed in a detection reagent containing H2O2,
luminol and an enhancer (ECL kit, Amersham, Aylesbury, UK) for
1 min at room temperature and signals were detected on DUPONT
Cronex-4 film. Any absence or significant decrease (more than
50%) in the intensity of one allele relative to the other was consid-
ered LOH (Figure 1).
Statistical analysis
A chi-squared test was used to assess the relationship between
LOH at 1p and prognostic variables. In the breast tumours LOH at
1p was compared with node status, tumour size, histological type,
age of diagnosis, steroid receptor content, S-phase fraction and
tumour ploidy. In the other tumours LOH at 1p was compared with
node status, tumour size and tumour differentiation. Survival
curves were calculated according to the method of Kaplan and
Meier (Kaplan and Meier, 1958). Tests of difference between
curves were made with the log-rank test for censored survival data
(Mantel, 1960). Multivariate analysis was performed with Cox’s
partially nonparametric regression model (Cox, 1972). The
Survival Tools for Statview Package (Abacus Concepts, Inc.,
Berkeley, CA, USA) was used for the statistical analysis.
Table 1 Information about the markers used in this study
Distance
Marker from Location Informative Tumours %
D1S243 samples with LOH
(cM)a LOH
D1S243 – 1p36.3 376 70 20
D1S468 6.4 1p36.3 340 86 25
D1S214 16.8 1p36.3 396 84 21
D1S228 33.2 1p36.1 333 65 20
D1S507 39.1 1p36.1 387 74 19
D1S436 43.6 1p36.1 258 59 23
D1S233 65.6 1p35 191 43 23
D1S201 66.7 1p35 246 53 22
D1S496 69.4 1p34.3 143 44 31
D1S209 98.8 1p32–p33 471 74 16
D1S216 110.1 1p32–p33 342 58 17
D1S207 120.5 1p32–p33 513 103 20
D1S488 121.0 1p32–p33 420 116 28
D1S167 128.4 1p31 426 104 24
D1S435 131.8 1p31 465 127 27
aThe markers have been mapped by Genethon from D1S243.
Table 2 Multivariate analysis [proportional-hazard (Cox) regression] of
survival in A 238 breast cancer patients and B 109 colorectal cancer patients
Parameter Univariate Multivariate RRa
P-value P-value 95% CI
A
LOH at 1p < 0.001 < 0.001 2.7 (1.5–4.9)
Axillary nodal involvement 0.024 0.015 1.8 (1.1–3.0)
Tumour sizeb < 0.001 0.381 1.3 (0.73–2.3)
S-phase fractionc 0.020 0.071 1.6 (0.96–2.7)
Progesterone receptord 0.040 0.371 1.3 (0.76–2.1)
B
LOH at 1p 0.089 0.055 1.9 (0.99–3.6)
Dukes gradee 0.024 0.017 2.2 (1.2–4.4)
Differentiationf 0.348 0.287 1.5 (0.70–3.4)
aRR = relative risk of dying in the multivariate analysis. bTumour size > 2 cm.
cS-phase fraction > 7%. dProgesterone receptor < 25 fmol mg–1 protein.
eDukes grade C and D. fDifferentiation grade III.
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Figure 1 The picture demonstrates a trinucleotide repeat polymorphism in
five matched normal (N) and tumour (T) tissues from breast cancer patients.
The microsatellite marker D1S488 was used in PCR analysis and the
amplified products separated by electrophoresis in a 6.5% polyacrylamide
8 M urea denaturing gel. Case numbers are shown at the top. Numbers to
the right indicate the size (in nucleotides) of the PCR product. Deletion can
be seen in tumours 982 and 1019. The fact that there is not a complete loss
of allele in these tumours is most probably due to contamination from normal
DNA in the tumour sample. The tumours 981 and 983 have normal
heterozygous allele patterns and patient sample 1020 is a homozygote1470 G Ragnarsson et al
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RESULTS
Loss of heterozygosity at chromosome 1p
Fifteen markers were used for the analysis of microsatellite poly-
morphism at the distal half of chromosome 1p in 683 primary
tumours. Representative results are shown in Figure 1. LOH with
at least one marker was detected in 369 (54%) while 46 tumours
showed LOH at all informative markers, suggesting complete
deletion of this region on chromosome 1p (132 cM). Figure 2
shows LOH at different markers for all tumour samples tested,
location of the markers and possible TSGs. There was a difference
in LOH frequency between tumours of different locations. The
types where LOH was detected in over 50% of the tumours were:
endometrium, 18/25 (72%); sarcoma, 9/14 (64%); breast, 146/238
(61%); lung, 38/63 (60%); colon and rectum, 60/109 (55%); ovary,
17/31 (55%); and stomach, 20/38 (53%). The LOH frequency
detected in thyroid, kidney and testis tumours was lower, i.e. 4/14
(29%), 22/73 (30%), and 11/30 (37%) respectively. There were
less than 10 samples of each of the following tumour types, so the
LOH frequency is of little reliability: mouth (2/5); oesophagus
(2/6); liver (3/6); pancreas (2/4); prostate (2/3); melanoma (3/3);
brain (2/5); phaeochromocytoma (1/1); adrenocortical cancer
(1/1); lymphoma (5/8); and unknown origin (2/6).
Figure 3 shows the frequency of LOH detected in 10 different
solid tumour locations, where the highest number of samples was
available. The pattern of LOH is similar but several differences
can be detected. Four peaks of LOH are detected with markers
D1S468, D1S507, D1S488 and D1S435 in stomach tumours
(Figure 3A). The two latter markers also show elevated LOH in
tumours of other tissues, e.g. colorectum, lung and breast, as well
as in sarcomas (Figure 3B, C, J, I). Furthermore, the D1S488
marker shows the highest detected LOH for an individual marker
in this study in sarcomas at 63% (Figure 3I). Markers D1S243 and
D1S436 also show high LOH in sarcoma, 50% and 60%, respec-
tively (Figure 3I). Interestingly, the highest detected LOH in
ovarian cancer is also by the D1S436 marker (Figure 3E). The
D1S468 marker also has a high LOH in endometrial cancer,
together with an elevation of LOH at markers D1S201 and
D1S167 (Figure 3D). There is an interesting difference in the LOH
pattern of markers D1S488, D1S167 and D1S435 in endometrial
cancer compared with most of the other tumours. Low frequency
was detected with all markers in testis, renal, and thyroid cancer,
with the exception of an elevation of LOH detected by marker
D1S216 in thyroid cancer (Figure 3F, G, H). The pattern of
microdeletions in breast and colorectal tumours is consistent with
the smallest region of overlap (SRO) in five regions: 1p36.3,
1p36.1, 1p35, 1p32 and 1p31 (Figure 4). A low number of
microdeletions and the complex pattern of LOH in lung tumours
makes mapping of SRO difficult. A complex pattern of LOH and
loss of all markers analysed is more frequently detected in lung
and colorectal tumours than tumours of breast and kidney. The
fraction of complete loss of chromosome 1p31-pter (all informa-
tive markers with LOH) was as following: testis, 0/30 (0%);
breast, 6/238 (2.5%); kidney, 3/73 (4.1%); stomach, 2/38 (5.3%);
thyroid, 1/14 (7.1%); colon/rectum, 14/109 (13%); lung, 9/63
(14%); ovaries, 5/31 (16%); endometrium, 5/25 (20%); and
sarcoma, 3/14 (21%). The mapping of the renal tumour samples
indicates two SROs in the 1p36.3–p36.1 region, distinct from the
1p
TP73 1p36.33 (Kaghad et al, 1997)
TR2 1p36.22-p36.3 (Kwon et al, 1997)
TNFR2 1p36.2-p36.3 (Kemper et al, 1991)
DR3 1p36.2 (Bodmer et al, 1997)
DR5 1p36.2 (Wu et al, 1997)
CDC2L1 1p36.2 (Lahti et al, 1994)
E2F2 1p36.11 (Lees et al, 1993)
RIZ 1p36.1 (Vorobyov et al, 1996)
PAX7 1p36.1 (Buyse et al, 1997)
ECK 1p36.1 (Sulman et al, 1997)
ERK 1p36.1 (Saito et al, 1995)
MOM1 1p35-p36.1 (Praml et al, 1995)
RPA2 1p35-p36.1 (Ozawa et al, 1993)
CDC42 1p35-p36 (Jensen et al, 1997)
LCK 1p35 (Volpi et al, 1994)
PTAFR 1p34.3-p35 (Chase et al 1996)
MYCL1 1p34.3 (Speleman et al, 1996)
TGFBR3 1p32-p33 (Johnson et al, 1995)
RAD54 1p32 (Rasio et al, 1997)
JAK1A 1p31.3-p32.3 (Modi et al, 1995)
p18 (INK4C) 1p32 (Lapointe et al, 1996)
IL12RB2 1p31.2 (Yamamoto et al, 1997)
GADD45 1p31.1-31.2 (Hey et al, 1996)
PTGER3 1p31.2 (Duncan et al, 1995)
PTGER 1p31.1 (Duncan et al, 1995)
36.3
36.2
36.1
35
34.3
34.2
34.1
33
32.3
32.2
32.1
31.3
31.2
31.1
Genes cM Markers (LOH%)
D1S243 (20%)
D1S468 (25%)
D1S214 (21%)
D1S228 (20%)
D1S507 (19%)
D1S436 (23%)
6.4
10.4
16.4
5.9
4.5
22.0
1.1
2.7
29.4
11.3
10.4
0.5
7.4
3.4
1.8
0.2
2.0
D1S233 (23%)
D1S201 (22%)
D1S496 (31%)
D1S209 (16%)
D1S216 (17%)
D1S207 (20%)
D1S488 (28%)
D1S167 (24%)
D1S435 (27%)
D1S188 (24%)
D1S424 (17%)
D1S236 (11%)
Data on markers D1S188,
D1S424 and D1S236 are
from Ragnarsson et al (1996)
Figure 2 Information about individual markers used in the study, their localization and percentage of LOH in tumour samples tested. The information for
markers D1S188, D1S424, and D1S236 is from our earlier work with breast cases. There is also information about possible TSG and their location on
chromosome 1pChromosome 1p in human solid tumours 1471
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SROs detected in the other three tumour types (Figure 4). A differ-
ence is also detected between the renal tumours and the other
tumour types in the 1p32 region. In the 1p31 region the same SRO
are detected, located between markers D1S435 and D1S167, in all
four tumour types (Figure 4).
Association with clinical and pathological variables
Chi-squared analysis comparing tumours with LOH at chromo-
some 1p with clinical and pathological variables showed a weak
association between LOH at 1p and high S-phase fraction (P =
0.021) in the breast tumours. There was also an association
between LOH at 1p and poor tumour differentiation (grade III) in
the colorectal cancer cases (P = 0.047), but association was not
found in other cancers (lung, stomach, endometrium, ovary,
kidney or testis). There was no significant association between
LOH at 1p and node status or tumour size in any cancer types
(breast, lung, colorectum, stomach, endometrium, ovary, kidney or
testis). There was no association between LOH at 1p in the breast
tumours and parameters such as histological type, age at diagnosis,
ploidy, or steroid receptor content. Furthermore, there was no
association between LOH at 1p and Duke’s grade in colorectal
cancer cases (data not shown).
Survival analysis
Breast cancer patients showed significant association between
LOH at chromosome 1p and overall survival as tested with a log-
rank test (P < 0.001). There was a significant separation of
survival curves (Figure 5A). Median follow-up time is 5.0 years.
When individual markers were analysed separately, with respect to
association with breast cancer patients’ overall survival, only one
marker showed significance with a long-rank test (P = 0.022) – the
D1S435 marker, located at the chromosome region 1p31.1.
Colorectal cancer patients showed a trend between LOH at 1p and
survival (P = 0.085) but the median follow-up time was only 2.1
years. Figure 5A shows the graphic representation of the survival
statistics in the breast cancer patients and Figure 5B shows the
survival statistics in colorectal cancer patients. Only 66 of the 146
breast cancer patients with LOH at 1p had metastasis in lymph
nodes but 80 were lymph node-negative. Multivariate analysis was
undertaken to evaluate the possible clinical relevance of LOH at
1p as a prognostic factor in breast cancer patients. The analysis
showed that breast cancer patients with tumours with LOH at 1p
had nearly a three-fold increase in relative mortality rate compared
with patients with tumours without LOH at 1p. The RR (relative
risk of dying in the multivariate analysis) was 2.7 (95% confidence
interval: 1.5–4.9) and P < 0.001. The only other factor of prog-
nostic value in the multivariate analysis was axillary nodal
involvement with RR = 1.8 (95% CI: 1.1–3.0) and P = 0.015
(Table 2A). A multivariate analysis in colorectal cancer patients
showed that patients with LOH at 1p had a nearly twofold increase
in relative mortality rate compared with patients with tumours
without LOH at 1p. The 95% confidence interval of the multi-
variate analysis was 0.99–3.6 and P = 0.055 (Table 2B).
DISCUSSION
In this study LOH at chromosome 1p was detected with at least one
marker in 54% of the tumours examined. The elevated frequency of
LOH with certain markers suggests five regions of deletion indi-
cating locations of putative TSGs. Known genes, located in these
regions, that could possibly play a role in tumorigenesis are shown
in Figure 2. The p53 homologue p73 on 1p36.33 (Kaghad et al,
1997) is one of these genes. A modifier gene of colon tumorigen-
esis (Mom1) in the mouse, which encodes secretory type II phos-
pholipase A2, affects the numbers of polyps developing as the
consequence of a mutation in the Apc gene (Min mouse). A human
homologue of the candidate for the Mom1 locus has been mapped
to 1p35–p36.1 (Praml et al, 1995). Other genes or homologues to
genes involved in cell growth and fidelity are: transcription factors,
E2F2 on 1p36.11 (Lees et al, 1993), PAX7 on 1p36.1 (Vorobyov et
al, 1997) and L-myc on 1p34.3 (Speleman et al, 1996); replication
protein gene RPA2 on 1p35 (Ozawa et al, 1993); death receptor
genes, TR2 (Kwon et al, 1997), TNFR2 (Kemper et al, 1991), DR3
(Bodmer et al, 1997) and DR5 (Wu et al, 1997), all on 1p36; other
receptor genes, PTAFR on 1p34.3–p35 (Chase et al, 1996),
TGFbR3 on 1p32–p33 (Johnson et al, 1995) and IL12Rb2 on
1p31.2 (Yamamoto et al, 1997); prostaglandin receptors, PTGER3
on 1p31.2 and PTGFR on 1p31.1 (Duncan et al, 1995); tyrosine
kinases, ECK on 1p36.1 (Sulman et al, 1997), LCK on 1p35 (Volpi
et al, 1994) and JAK1 on 1p31.3–p32.3 (Modi et al, 1995); dual
specific kinase ERK (Saito et al, 1995) on 1p36.1; repair protein
genes, RAD54 on 1p32 (Rasio et al, 1997); and GADD45 on
1p31.1–p31.2 (Hey et al, 1996); cell cycle control proteins,
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CDC2L1 (Lahti et al, 1994) on 1p36.2, RIZ on 1p36.1 (Buyse et al,
1996) and p18 (INK4C) on 1p32 (Lapointe et al, 1996).
A difference in LOH was detected between different tumour
types. Some tumour types, testis and renal cancer, show low
frequency of LOH while other tumour types have a high frequency
of LOH, the highest in sarcomas and endometrial cancers. A
subset of markers show elevated frequency of LOH in a number of
different tumour types, suggesting that loss of a given TSG might
be involved in pathogenesis of tumour growth in different tissues.
Otherwise, a distinct pattern of LOH was detected in individual
tumour types, reflecting multiple TSGs, that could be differentially
inactivated in tumorigenesis. Furthermore, the study shows that
LOH at 1p can be detected in tumours of the mouth, oesophagus,
liver, pancreas, prostate, brain and adrenal gland, as well as
melanoma and lymphoma.
There was a weak significant association between LOH at 1p
and high S-phase fraction in breast tumours and between LOH and
poor tumour differentiation in colorectal tumours. In breast cancer
patients, there seems to be no association between LOH at 1p and
age of onset, tumour ploidy or steroid receptor content.
Furthermore, no association was detected between LOH at 1p and
tumour size or nodal metastasis in tumours of the breast, stomach,
colorectum, lung, endometrium, ovary, kidney or testis. LOH at 1p
does not appear to be associated with the nodal metastasis step in
carcinogenesis. LOH at 1p is an independent prognostic factor for
the breast cancer patients and is in line with our earlier finding
with less patient material and a shorter follow-up time
(Ragnarsson et al, 1996). Furthermore, LOH at 1p seems to be a
prognostic factor in colorectal cancer also, though in this study the
association is not significant probably due to the short follow-up
time. In a different study it was concluded that allelic loss in the
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Figure 5 Cumulative percent surviving at different time intervals for (A)
breast cancer patients and (B) colorectal cancer patients. Time intervals are
given in years. The median follow-up time is (A) 5.0 years and (B) 2.1 years.
The upper line shows patients without LOH on 1p but the lower line shows
patients with LOH on 1p. The number of patients at risk at (A) time 0, 2, 5
years, and (B) 0, 1.5 and 3 years, are shown for both categories1p36 and 1p32 regions of chromosome 1 appears to be an
independent predictor of poor prognosis in patients with adeno-
carcinoma of the colon (Ogunbiyi et al, 1997).
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